For: | Aversa A. Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes 2010; 1(1): 3-7 [PMID: 21537421 DOI: 10.4239/wjd.v1.i1.3] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v1/i1/3.htm |
Number | Citing Articles |
1 |
O.A. El-Kawy, J.A. García-Horsman, R.K. Tuominen. Labelling, molecular modelling and biological evaluation of vardenafil: a potential agent for diagnostic evaluation of erectile dysfunction. Applied Radiation and Isotopes 2016; 118: 258 doi: 10.1016/j.apradiso.2016.09.023
|
2 |
L. Sjögren, J. Olausson, L. Strindberg, R. Mobini, P. Fogelstrand, L. Mattsson Hultén, P.‐A. Jansson. Postprandial effects of the phosphodiesterase‐5 inhibitor tadalafil in people with well‐controlled Type 2 diabetes mellitus: a randomized controlled trial. Diabetic Medicine 2016; 33(9): 1299 doi: 10.1111/dme.12999
|
3 |
Luigi Di Luigi, Francesco Botrè, Stefania Sabatini, Massimiliano Sansone, Monica Mazzarino, Laura Guidetti, Carlo Baldari, Andrea Lenzi, Daniela Caporossi, Francesco Romanelli, Paolo Sgrò. Acute effects of physical exercise and phosphodiesterase’s type 5 inhibition on serum 11β-hydroxysteroid dehydrogenases related glucocorticoids metabolites: a pilot study. Endocrine 2014; 47(3): 952 doi: 10.1007/s12020-014-0185-2
|
4 |
Subhashis Pal, Mamunur Rashid, Sandeep Kumar Singh, Konica Porwal, Priya Singh, Riyazuddin Mohamed, Jiaur R. Gayen, Muhammad Wahajuddin, Naibedya Chattopadhyay. Skeletal restoration by phosphodiesterase 5 inhibitors in osteopenic mice: Evidence of osteoanabolic and osteoangiogenic effects of the drugs. Bone 2020; 135: 115305 doi: 10.1016/j.bone.2020.115305
|
5 |
Cristina Antinozzi, Paolo Sgrò, Luigi Di Luigi. Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. International Journal of Endocrinology 2020; 2020: 1 doi: 10.1155/2020/7078108
|
6 |
Hayat Ouassou, Nour Elhouda Daoudi, Saliha Bouknana, Rhizlan Abdnim, Mohamed Bnouham. A Review of Antidiabetic Medicinal Plants as a Novel Source of
Phosphodiesterase Inhibitors: Future Perspective of New Challenges
Against Diabetes Mellitus. Medicinal Chemistry 2024; 20(5): 467 doi: 10.2174/0115734064255060231116192839
|
7 |
Guglielmo Duranti, Roberta Ceci, Paolo Sgrò, Stefania Sabatini, Luigi Di Luigi. Influence of the PDE5 inhibitor tadalafil on redox status and antioxidant defense system in C2C12 skeletal muscle cells. Cell Stress and Chaperones 2017; 22(3): 389 doi: 10.1007/s12192-017-0778-9
|
8 |
Ying Wu, Zhe Wang, Lu Han, Zhihao Guo, Bohua Yan, Lili Guo, Huadong Zhao, Mengying Wei, Niuniu Hou, Jing Ye, Zhe Wang, Changhong Shi, Suling Liu, Ceshi Chen, Suning Chen, Ting Wang, Jun Yi, JianPing Zhou, Libo Yao, Wenxia Zhou, Rui Ling, Jian Zhang. PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer. Molecular Therapy 2022; 30(7): 2603 doi: 10.1016/j.ymthe.2022.03.003
|
9 |
Min-Kyung Lee, Jae-Hyuk Lee, Seo-Young Sohn, Seo Yeon Lee, Tae-Yoong Jeong, Sae Chul Kim. Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study. Diabetology & Metabolic Syndrome 2022; 14(1) doi: 10.1186/s13098-022-00825-w
|
10 |
Enis Rauf Coskuner, Burak Ozkan. Reno-protective effects of Phosphodiesterase 5 inhibitors. Clinical and Experimental Nephrology 2021; 25(6): 585 doi: 10.1007/s10157-021-02051-6
|
11 |
Paula Proença, Carla Mustra, Mariana Marcos, João Miguel Franco, Francisco Corte-Real, Duarte Nuno Vieira. Validated UPLC-MS/MS assay for the determination of synthetic phosphodiesterase type-5 inhibitors in postmortem blood samples. Journal of Forensic and Legal Medicine 2013; 20(6): 655 doi: 10.1016/j.jflm.2013.03.002
|
12 |
Salah Boudjadi, Julie C Carrier, Jean-François Beaulieu. Integrin α1 subunit is up-regulated in colorectal cancer. Biomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-16
|
13 |
Cristina ANTINOZZI, Emanuela A. GRECO, Paolo SGRÒ, Ivan DIMAURO, Antonio AVERSA, Luigi DI LUIGI. Effects of tadalafil on skeletal muscle tissue: exploring interactions and novel mechanisms of action. Minerva Endocrinology 2023; 48(2) doi: 10.23736/S2724-6507.21.03698-8
|
14 |
P. Krause, H. Flikweert, M. Monin, A. Seif Amir Hosseini, G. Helms, G. Cantanhede, B. M. Ghadimi, S. Koenig. Increased growth of colorectal liver metastasis following partial hepatectomy. Clinical & Experimental Metastasis 2013; 30(5): 681 doi: 10.1007/s10585-013-9572-y
|
15 |
Manuel González-Ortiz, Esperanza Martínez-Abundis, Diana M. Hernández-Corona, Alejandra M. Ramírez-Rodríguez. Effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men. Acta Clinica Belgica 2017; 72(5): 326 doi: 10.1080/17843286.2017.1293759
|
16 |
Jheelam Banerjee, Antje Bruckbauer, Teresa Thorpe, Michael B. Zemel. Biphasic Effect of Sildenafil on Energy Sensing is Mediated by Phosphodiesterases 2 and 3 in Adipocytes and Hepatocytes. International Journal of Molecular Sciences 2019; 20(12): 2992 doi: 10.3390/ijms20122992
|
17 |
Luigi Di Luigi, Clarissa Corinaldesi, Marta Colletti, Sabino Scolletta, Cristina Antinozzi, Gabriella B. Vannelli, Elisa Giannetta, Daniele Gianfrilli, Andrea M. Isidori, Silvia Migliaccio, Noemi Poerio, Maurizio Fraziano, Andrea Lenzi, Clara Crescioli. Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. Inflammation 2016; doi: 10.1007/s10753-016-0359-6
|
18 |
F. Marampon, C. Antinozzi, C. Corinaldesi, G. B. Vannelli, E. Sarchielli, S. Migliaccio, L. Di Luigi, A. Lenzi, C. Crescioli. The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism. Endocrine 2018; 59(3): 602 doi: 10.1007/s12020-017-1378-2
|
19 |
Agnieszka Kilanowska, Agnieszka Ziółkowska. Role of Phosphodiesterase in the Biology and Pathology of Diabetes. International Journal of Molecular Sciences 2020; 21(21): 8244 doi: 10.3390/ijms21218244
|
20 |
Wei Liu, Xiaojun Tian, Ti Wu, Le Liu, Yanghongyun Guo, Changhua Wang. PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes. International Journal of Endocrinology 2019; 2019: 1 doi: 10.1155/2019/3054820
|
21 |
Emanuel Fryk, Vagner Ramon Rodrigues Silva, Marco Bauzá-Thorbrügge, Martin Schmelz, Li-Ming Gan, Lena Strindberg, Per-Anders Jansson. Feasibility of high-dose tadalafil and effects on insulin resistance in well-controlled patients with type 2 diabetes (MAKROTAD): a single-centre, double-blind, randomised, placebo-controlled, cross-over phase 2 trial. eClinicalMedicine 2023; 59: 101985 doi: 10.1016/j.eclinm.2023.101985
|